Melt-in-Mouth Multi-particulate System for the Treatment of ADHD: A Convenient Platform for Pediatric Use
Tóm tắt
Generally, pellets obtained from extrusion/spheronization, containing microcrystalline cellulose (MCC), do not disintegrate. An attempt has been made to develop melt-in-mouth pellets of taste-masked atomoxetine hydrochloride, using extrusion-spheronization, for pediatric patients. Melt-in-mouth pellets were prepared using extrusion-spheronization method and optimized using 33 FFD. MCC (X1, %), mannitol (X2, %) and Indion 414: Pharmaburst 500 ratio (X3, ratio) were the factors (independent variables) studied, whereas responses studied (dependent variables) were friability (Y1, %), yield (Y2, %) shape (Y3, roundness) in vitro disintegration time (Y4, seconds). The optimized formulation obtained from FFD was characterized for friability, shape and morphology, in vitro disintegration time, porosity, moisture uptake, in vitro release study and in vivo taste and disintegration time in healthy human volunteers. Randomized, two-treatment, two-sequence, two-period, single dose, crossover sensory evaluation study of taste-masked melt-in-mouth pellet was carried out in 10 healthy human subjects. A statistically significant polynomial mathematical relationship was generated between the factors and responses to obtain an optimized formulation. The optimized formulation was characterized (in vitro and in vivo) and exhibited a rapid drug release in vitro attributed to fast disintegration of pellets and high solubility of drug in 0.1 N HCl and buffer (pH 6.8). In vivo, 40% of volunteers ranked taste-masked optimized formulation as slightly bitter while 60% ranked it as no taste. The optimized pellets were conveniently administered in volunteers and exhibited rapid in-vivo disintegration in the oral cavity. Melt-in-mouth pellets can be a used as a platform technology for administering drugs to paediatric patients accurately and conveniently resulting in patient compliance.
Tài liệu tham khảo
Krause J, Breitkreutz J. Improving drug delivery in paediatric medicine. Pharma Med. 2008;22:41–50.
Mohan MS. Pharmaceutical Development with focus on paediatric formulations. Mumbai: WHO / FIP Training Workshop; 2008.
Breitkreutz J, Boos J. Paediatric and geriatric drug delivery. Expert Opin Drug Deliv. 2007;4(1):37–45.
Nunn T, Williams J. Formulation of medicines for children. Br J Clin Pharmacol. 2004;59:674–6.
Siddiqui N, Garg G, Sharma P. Fast dissolving tablets: preparation, characterization and evaluation. Int J Pharm Sci Rev Res. 2010;4:87–96.
Standing JF, Tuleu C. Paediatric formulations-getting to the heart of the problem. Int J Pharm. 2005;300:56–66.
Shah RB, Collier JS, Sayeed VA, Bryant A, Habib MJ, Khan MA. Tablet splitting of a narrow therapeutic index drug: a case with levothyroxine sodium. AAPS PharmSciTech. 2010;11:1359–67.
Kayumba PC, Huyghebaert N, Cordella C, Ntawukuliryayo JD, Vervaet C, Remon JP. Quinine sulphate pellets for flexible pediatric drug dosing: formulation development and evaluation of taste-masking efficiency using the electronic tongue. Eur J Pharm Biopharm. 2007;66:460–5.
Sosnik A, Seremeta KP, Imperiale JC, Chiappetta DA. Novel formulation and drug delivery strategies for the treatment of pediatric poverty-related diseases. Expert Opin Drug Deliv. 2012;9:303–23.
Garland M, Kirkpatrick P. Atomoxetine hydrochloride. Nat Rev Drug Disco. 2004;3:385–6.
NIMH. Attention-deficit/hyperactivity disorder. Bethesda, USA: US Department of Health and Human Services, National Institutes of Health; 2012.
Mermey MS, Roy AK. Atomoxetine Solution. World Patent WO2014204513, December 24, 2014.
Venkatesh GM, Harmon TM, Taylor J. Orally disintegrating tablets of atomoxetine. US patent 8747895 B2, June 10, 2014.
Jain SP, Mehta DC, Shah SP, Singh PP, Amin PD. Melt-in-mouth pellets of fexofenadine hydrochloride using crospovidone as an extrusion–spheronisation aid. AAPS PharmSciTech. 2010;11(2):917–23.
Joshi A, Pund S, Nivsarkar M, Vasu K, Shishoo C. Dissolution test for site-specific release isoniazid pellets in USP apparatus 3 (reciprocating cylinder): optimization using response surface methodology. Eur J Pharm Biopharm. 2008;69:769–75.
Howard MA, Neau SH, Marvin JS. PEO and MPEG in high drug load extruded and spheronized beads that are devoid of MCC. Int J Pharm. 2006;307:66–76.
Koo OMY, Heng PWS. The influence of microcrystalline cellulose grade on shape and shape distributions of pellets produced by extrusion-spheronization. Chem Pharm Bull. 2001;49(11):1383–7.
Chopra R, Newton JM, Alderborn G, Podczeck F. Preparation of pellets of different shape and their characterization. Pharm Dev Technol. 2001;6:495–503.
Steckel H, Mindermann-Nogly F. Production of chitosan pellets by extrusion/spheronization. Eur J Pharm Biopharm. 2004;57:105–14.
Abdalla A, Mader K. Preparation and characterization of a self-emulsifying pellet formulation. Eur J Pharm Biopharm. 2007;66:220–6.
Tho I, Sande SA, Kleinebudde P. Disintegration pellets form a water insoluble pectin derivative produced by extrusion/spheronisation. Eur J Pharm Biopharm. 2003;56:371–80.
Tripathi R, Mishra B. Preparation and evaluation of composite microspheres of polyacrylamide-grafted polysaccharide. J Appl Polym Sci. 2013;130:2912–22.
Rouseff RL, Matthews RF. Nomilin, Taste threshold and relative bitterness. J Food Sci. 1984;49:777–9.
Rowe RC, Sheskey PJ, Quinn ME. Handbook of pharmaceutical excipients. 6th ed. IL, USA: Pharmaceutical Press; 2009.
Pund S, Joshi A, Vasu K, Nivsarkar M, Shishoo C. Gastroretentive delivery of rifampicin: in vitro mucoadhesion and in vivo gamma scintigraphy. Int J Pharm. 2011;411:106–12.
Otero-Espinar FJ, Luzardo-Alvarez A, Blanco-Méndez J. Non-MCC materials as extrusion-spheronization aids in pellets production. J Drug Deliv Sci Technol. 2010;20:303–18.
Heng PWS, Koo OMY. A study of the effects of the physical characteristics of microcrystalline cellulose on performance in extrusion spheronization. Pharm Res. 2001;18(4):480–7.
Chamsai B, Sriamornsak P. Novel disintegrating microcrystalline cellulose pellets with improved drug dissolution performance. Powder Technol. 2013;233:278–85.
Buck ML. Alternative forms of oral drug delivery for pediatric patients. Pediatr Pharmacol. 2013;19:1–6.
Sosnik A, Carcaboso AM. Nanomedicines in the future of pediatric therapy. Adv Drug Deliv Rev. 2014;73:140–61.
Shukla D, Tripathi R, Mishra B. Taste masking in oral drug delivery systems: a technological update. Pharmstudent. 2010;25:58–64.